Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy

Figures

• 

  Figure 1. Study design. Atherosclerotic Cardiovascular Disease (ASCVD): Acute coronary syndrome (ACS), stable angina, unstable angina, stroke or transient ischemic attack (TIA), peripheral arterial disease (PAD), and revascularization procedures (percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or other revascularization procedures).

• 

  Figure 2. (a) Lipid Lowering Therapy (LLT) in ASCVD patients within 6 months from the discharge. (b) Lipid Lowering Therapy (LLT) in ASCVD patients within 6 months from the discharge stratified by LDL-C category. * With and without ezetimibe. ** With and without ezetimibe and/or statin therapy. 1 High-intensity LLT included atorvastatin 40–80 mg, rosuvastatin 20–40 mg and PCSK9i. 2 Low-/moderate-intensity statin included all other statin types and doses. Abbreviations: ASCVD, atherosclerotic cardiovascular disease; LLT, LDL-C-lowering therapy; PCSK9i, proprotein convertase subtilisin/kexin 9 inhibitor.

• 

  Figure 3. Lipid Lowering Therapy (LLT) in ASCVD patients within 6 months from the discharge stratified by sex and age (A) and ASCVD condition (B). Type of Lipid Lowering Therapy (LLT) in ASCVD patients within 6 months from the discharge stratified by sex and age (C) and ASCVD condition (D). * Procedures including percutaneous coronary intervention, coronary artery bypass surgery, or other revascularization procedures. ** Without procedures. Abbreviations: ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; PAD, peripheral arterial disease; TIA, transient ischemic attack.